Our Take On Cardiovascular Systems, Inc.’s (NASDAQ:CSII) CEO Salary

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

In 1970 Scott Ward was appointed CEO of Cardiovascular Systems, Inc. (NASDAQ:CSII). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. Next, we’ll consider growth that the business demonstrates. And finally – as a second measure of performance – we will look at the returns shareholders have received over the last few years. This process should give us an idea about how appropriately the CEO is paid.

View our latest analysis for Cardiovascular Systems

How Does Scott Ward’s Compensation Compare With Similar Sized Companies?

At the time of writing our data says that Cardiovascular Systems, Inc. has a market cap of US$1.4b, and is paying total annual CEO compensation of US$3.4m. (This figure is for the year to June 2018). While this analysis focuses on total compensation, it’s worth noting the salary is lower, valued at US$650k. When we examined a selection of companies with market caps ranging from US$1.0b to US$3.2b, we found the median CEO total compensation was US$4.1m.

So Scott Ward receives a similar amount to the median CEO pay, amongst the companies we looked at. Although this fact alone doesn’t tell us a great deal, it becomes more relevant when considered against the business performance.

The graphic below shows how CEO compensation at Cardiovascular Systems has changed from year to year.

NasdaqGS:CSII CEO Compensation, May 31st 2019
NasdaqGS:CSII CEO Compensation, May 31st 2019

Is Cardiovascular Systems, Inc. Growing?

On average over the last three years, Cardiovascular Systems, Inc. has grown earnings per share (EPS) by 128% each year (using a line of best fit). It achieved revenue growth of 13% over the last year.

This demonstrates that the company has been improving recently. A good result. It’s a real positive to see this sort of growth in a single year. That suggests a healthy and growing business. It could be important to check this free visual depiction of what analysts expect for the future.

Has Cardiovascular Systems, Inc. Been A Good Investment?

Boasting a total shareholder return of 131% over three years, Cardiovascular Systems, Inc. has done well by shareholders. As a result, some may believe the CEO should be paid more than is normal for companies of similar size.

In Summary…

Scott Ward is paid around what is normal the leaders of comparable size companies.

The company is growing earnings per share and total shareholder returns have been pleasing. Although the pay is a normal amount, some shareholders probably consider it fair or modest, given the good performance of the stock. So you may want to check if insiders are buying Cardiovascular Systems shares with their own money (free access).

If you want to buy a stock that is better than Cardiovascular Systems, this free list of high return, low debt companies is a great place to look.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.